Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP Trial

Recursion Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Recursion agreed with the FDA on the primary endpoint for a planned global Phase III trial of REC-4881 in familial adenomatous polyposis (FAP). The event-driven study is planned to start in 2027 and will track qualifying events including polyps, surgeries, cancer and death.
  • In Phase II, about one-third of post-colectomy patients had a greater than 65% reduction in polyp burden after 13 weeks; the company said much of the effect persisted for three months after treatment stopped.
  • Recursion also reported three partial responses in early REC-1245 cancer testing and expects updates on that program and a brain-penetrant LSD1 inhibitor in the second half of 2027. CEO Najat Khan said partnerships have generated about $535 million in cash inflows and the company has reduced cash burn by 40%.
  • Five stocks to consider instead of Recursion Pharmaceuticals.

Recursion Pharmaceuticals NASDAQ: RXRX has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial adenomatous polyposis, or FAP, CEO Najat Khan said at the Jefferies Healthcare Conference in London.

The company plans to begin the global registrational study of REC-4881 in 2027. The trial will enroll adults who have had their colons removed and will measure the time until a patient experiences a qualifying event, Khan said.

The composite endpoint includes dysplasia, certain surgeries, cancer and death. It also includes the excision of polyps measuring at least 10 millimeters anywhere in the gastrointestinal tract, a component Khan said was newly incorporated following discussions with the FDA.

FAP trial follows Phase II results

FAP is a rare inherited disease in which patients develop numerous gastrointestinal polyps. Khan said there are no approved therapies and estimated the potential market at $15 billion, including more than 50,000 patients in the U.S. and five major European markets.

Patients often undergo colon removal, but polyps can continue to develop in the upper gastrointestinal tract and rectum, requiring surveillance and further procedures, Khan said.

In Recursion’s Phase II study of post-colectomy patients, approximately one in three saw a reduction of more than 65% in polyp burden, measured by size and number, after 13 weeks of treatment, according to Khan. She said reductions were observed in both the upper and lower gastrointestinal tract and that most of the reduction was sustained in patients followed for three months after stopping treatment.

Khan cited one patient whose number of upper gastrointestinal polyps larger than 5 millimeters fell from 96 to one after 13 weeks. She said the initial count would have met the criteria for surgery, while the reduced count would not.

The Phase III trial will be event-driven and will include a prespecified interim analysis. Khan did not provide the number of events or timing needed for that analysis. Jefferies biotech analyst Dennis Ding said the company had committed to starting the study in the second half of 2027; Khan said Recursion would provide more detail on the timeline.

Early cancer data and pipeline plans

Khan also discussed REC-1245, an experimental RBM39 degrader being studied in solid tumors. She said monotherapy dose escalation produced three partial responses: two confirmed responses in heavily pretreated patients with endometrial cancer and one unconfirmed response in a patient with hepatocellular carcinoma.

The company is recruiting for an endometrial cancer expansion cohort and expects to share early monotherapy data in the second half of 2027. Khan said that update would likely include a handful of patients. Recursion is also exploring other solid tumors and potential combinations, including with antibody-drug conjugates or immunotherapies.

Khan described the tolerability profile observed so far as manageable, with fatigue and anemia largely at grades one and two around the 45-milligram daily dose. She said the company was focused on enrolling patients and assessing antitumor activity before drawing further conclusions.

Recursion also expects data in the second half of 2027 from a brain-penetrant LSD1 inhibitor, Khan said. An oral ENPP1 inhibitor is in investigational new drug-enabling work.

Partnerships and AI platform

Khan said Recursion used its artificial intelligence platform to identify the biological rationale for REC-4881 and, for REC-1245, to identify the target, design the degrader and help select patient populations.

She also highlighted partnerships with Sanofi and Roche Genentech. Sanofi recently optioned an oral dual-inhibitor molecule designed using Recursion’s platform, while Roche Genentech has optioned novel targets from the company’s biological maps, she said. Khan said Recursion sees potential for further milestones under both partnerships.

Across its partnerships, Recursion has surpassed approximately $535 million in cash inflows, Khan said. She added that the company had reduced its cash burn by 40% and recently completed an oversubscribed financing round.

About Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines